🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to health experts.

A Global Challenge

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million new cases each year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This approval marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Data and Global Access

Based on findings released by a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which combines a dual-drug approach. The trial included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to register and commercialise the drug in a wide range of developing nations.

Doctors on the front lines have shared hope. Access to a easy-to-administer therapy of this kind is hailed as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the disease for individuals and to prevent the spread of untreatable gonorrhoea around the world.